Background: The etiology and pathogenesis of odontogenic lesions remain to be determined. Previous studies have identified epigenetic and genetic alterations that may be relevant to lesions progression and development. Hypermethylation of the Ras association domain family protein 1A (RASSF1A) has been observed in a variety of human cancers. However, the methylation status of RASSF1A in odontogenic lesions remains unknown. Thus, the aim of this study was to investigate the prevalence of RASSFA promoter hypermethylation and v-raf murine sarcoma viral oncogene homolog B V600E mutant (BRAF V600E) expression as well as the correlations between these alterations and clinicopathological features of patients with odontogenic lesions. Methods: We subjected 66 formalin-fixed, paraffin-embedded odontogenic lesions [ameloblastoma (AM), 21; ameloblastic carcinoma (AC), 6; odontogenic keratocyst (OKC), 19; and dentigerous cyst (DC), 20] to methylation-specific polymerase chain reaction to determine RASSF1A hypermethylation and immunohistochemistry to detect BRAF V600E protein expression. Results: We observed RASSF1A hypermethylation in 20% (4/20; methylation could not be detected in one lesion), 100% (6/6), 26.3% (5/19), and 5% (1/20) of AM, AC, OKC, and DC samples, respectively. RASSF1A methylation was significantly more frequently observed in AC relative to AM, OKC, and DC (p < 0.001). Moreover, 85.7% (18/21) and 83.3% (5/6) AM and AC samples, respectively, were BRAF V600E-positive, whereas all OKC and DC sample were BRAF V600E-negative. No correlations of RASSF1A methylation and BRAF V600E expression with clinicopathological features were observed. Conclusions: Concomitant RASSF1A methylation and positive BRAF V600E expression are commonly observed in AC, which may contribute to AC tumorigenesis.
References
[1]
Raj, A., Ramesh, G., Nagarajappa, R., Pandey, A. and Raj, A. (2017) Prevalence of Odontogenic Lesions among the Kanpur Population: An Institutional Study. Journal of Experimental Therapeutics and Oncology, 12, 35-42.
[2]
Takata, T. and Slootweg, P.J. (2017) Introduction to Odontogenic and Maxillofacial Bone Tumours. In: El-Naggar, A.K., Chan, J.K.C., Grandis, J.R., Takata, T. and Slootweg, P.J., Eds., WHO Classification of Head and Neck Tumours, 4th Edition, IARC, Lyon, 205.
[3]
Chae, M.P., Smoll, N.R., Hunter-Smith, D.J. and Rozen, W.M. (2015) Establishing the Natural History and Growth Rate of Ameloblastoma with Implications for Management: Systematic Review and Meta-Analysis. PLoS ONE, 10, e0117241. https://doi.org/10.1371/journal.pone.0117241
[4]
Cox, D.P., Muller, S., Carlson, G.W. and Murray, D. (2000) Ameloblastic Carcinoma Ex Ameloblastoma of the Mandible with Malignancy-Associated Hypercalcemia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 90, 716-722. https://doi.org/10.1067/moe.2000.109076
[5]
Jaafari-Ashkavandi, Z., Mehranmehr, F. and Roosta, E. (2019) MCM3 and Ki67 Proliferation Markers in Odontogenic Cysts and Ameloblastoma. Journal of Oral Biology and Craniofacial Research, 9, 47-50. https://doi.org/10.1016/j.jobcr.2018.09.003
[6]
Stoelinga, P.J.W. (2019) Keratocystic Odontogenic Tumor (KCOT) Has Again Been Renamed Odontogenic Keratocyst (OKC). International Journal of Oral & Maxillofacial Surgery, 48, 415-416. https://doi.org/10.1016/j.ijom.2018.07.020
[7]
Pfeifer, G.P. and Dammann, R. (2005) Methylation of the Tumor Suppressor Gene RASSF1A in Human Tumors. Biochemistry (Moscow), 70, 576-583. https://doi.org/10.1007/s10541-005-0151-y
[8]
Donninger, H., Vos, M.D. and Clark, G.J. (2007) The RASSF1A Tumor Suppressor. Journal of Cell Science, 15, 3163-3172. https://doi.org/10.1242/jcs.010389
[9]
Wen, G., Wang, H. and Zhong, Z. (2018) Associations of RASSF1A, RARβ, and CDH1 Promotor Hypermethylation with Oral Cancer Risk a PRISMA-Compliant Meta-Analysis. Medicine (Baltimore), 97, e9971. https://doi.org/10.1097/MD.0000000000009971
[10]
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W.H., Ladenson, P.W. and Sidransky, D. (2003) BRAF Mutation in Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 95, 625-627. https://doi.org/10.1093/jnci/95.8.625
[11]
Chang, F., Steelman, L.S., Lee, J.T., Shelton, J.G., Navolanic, P.M., Blalock, W.L., Franklin, R.A. and McCubrey, J.A. (2003) Signal Transduction Mediated by the Ras/Raf/MEK/ERK Pathway from Cytokine Receptors to Transcription Factors: Potential Targeting for Therapeutic Intervention. Leukemia, 17, 1263-1293. https://doi.org/10.1038/sj.leu.2402945
[12]
Ducreux, M., Chamseddine, A., Laurent-Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samallin, E., Boige, V., Malka, D. and Gelli, M. (2019) Molecular Targeted Therapy of BRAF-Mutant Colorectal Cancer. Therapeutic Advances in Medical Oncology, 11, 1-15. https://doi.org/10.1177/1758835919856494
[13]
Lapthanasupkul, P., Juengsomjit, R., Poomsawat, S. and Arayapisit, T. (2018) Expression Profile of Polycomb Group Proteins in Odontogenic Keratocyst and Ameloblastoma. Actahistochemica, 120, 215-220. https://doi.org/10.1016/j.acthis.2018.01.009
[14]
Kumamoto, H. (2006) Molecular Pathology of Odontogenic Tumors. Journal of Oral Pathology & Medicine, 35, 65-74. https://doi.org/10.1111/j.1600-0714.2006.00380.x
[15]
Li, T.J. (2011) The Odontogenic Keratocyst: A Cyst or a Cystic Neoplasm? Journal of Dental Research, 90, 133-142. https://doi.org/10.1177/0022034510379016
[16]
Diniz, M.G., Gomes, C.C., de Sousa, S.F., Xavier, G.M. and Gomez, R.S. (2017) Oncogenic Signaling Pathways in Benign Odontogenic Cysts and Tumors. Oral Oncology, 72, 165-173. https://doi.org/10.1016/j.oraloncology.2017.07.021
[17]
Pereira, N.B., Pereira, K.M., Coura, B.P., Diniz, M.G., de Castro, W.H., Gomes, C.C. and Gomez, R.S. (2016) BRAF V600E Mutation in the Diagnosis of Unicystic Ameloblastoma. Journal of Oral Pathology & Medicine, 45, 780-785. https://doi.org/10.1111/jop.12443
[18]
Brown, N.A., Rolland, D., McHugh, J.B., Weigelin, H.C., Zhao, L., Lim, M.S., Elenitoba-Johnson, K.S. and Betz, B.L. (2014) Activating FGFR2-RAS-BRAF Mutations in Ameloblastoma. Clinical Cancer Research, 20, 5517-5526. https://doi.org/10.1158/1078-0432.CCR-14-1069
[19]
Kurppa, K.J., Caton, J., Morgan, P.R., Ristimäki, A., Ruhin, B., Kellokoski, J., Elenius, K. and Heikinheimo, K. (2014) High Frequency of BRAF V600E Mutations in Ameloblastoma. Journal of Pathology, 232, 492-498. https://doi.org/10.1002/path.4317
[20]
Fregnani, E.R., Perez, D.E., Paes de Almeida, O., Fonseca, F.P., Soares, F.A., Castro-Junior, G. and Alves, F.A. (2017) BRAF-V600E Expression Correlates with Ameloblastoma Aggressiveness. Histopathology, 70, 473-484. https://doi.org/10.1111/his.13095
[21]
do Canto, A.M., da Silva Marcelino, B.M.R, Schussel, J.L., Wastner, B.F., Sassi, L.M., Corrêa, L., de Freitas, R.R., Hasséus, B., Kjeller, G., Junior, C.A.L and Braz-Silva, P.H. (2019) Immunohistochemical Analysis of BRAF V600E Mutation in Ameloblastomas. Clinical Oral Investigation, 23, 779-784. https://doi.org/10.1007/s00784-018-2494-y
[22]
Kelppe, J., Thoren, H., Ristimaki, A., Haglund, C., Sorsa, T. and Hagstrom, J. (2019) BRAF V600E Expression in Ameloblastomas-A 36-Patient Cohort from Helsinki University Hospital. Oral Diseases, 25, 1164-1174. https://doi.org/10.1111/odi.13072
[23]
Cha, Y.H., Cho, E.S., Kang, H.E., Ko, J., Nam, W., Kim, H.J., Kim, N.H., Kim, H.S., Cha, I.H. and Yook, J.I. (2017) Frequent Oncogenic BRAFV600E Mutation in Odontogenic Keratocyst. Oral Oncology, 74, 62-67. https://doi.org/10.1016/j.oraloncology.2017.09.016
[24]
Franca, J.A., de Sousa, S.F., Diniz, M.G., Pereira, T.D.S.F., de Resende, T.A.C., Santos, J.N.D., Gomez, R.S. and Gomes, C.C. (2018) Absence of BRAFV600E Mutation in Odontogenic Keratocysts. Journal of Oral Pathology & Medicine, 47, 186-191. https://doi.org/10.1111/jop.12671
[25]
Moreira, P.R., Guimaraes, M.M., Guimaraes, A.L., Diniz, M.G., Gomes, C.C., Brito, J.A. and Gomez, R.S. (2009) Methylation of p16, p21, p27, RB1 and p53 Genes in Odontogenic Keratocysts. Journal of Oral Pathology & Medicine, 38, 99-103. https://doi.org/10.1111/j.1600-0714.2008.00718.x
[26]
Moreira, P.R., Guimaraes, M.M., Gomes, C.C., Diniz, M.G., Brito, J.A., de Castro, W.H. and Gomez, R.S. (2009) Methylation Frequencies of Cell-Cycle Associated Genes in Epithelial Odontogenic Tumours. Archives of Oral Biology, 54, 893-897. https://doi.org/10.1016/j.archoralbio.2009.07.006
[27]
Farias, L.C., Gomes, C.C., Rodrigues, M.C., de Castro, W.H., Lacerda, J.C., Ferreira, E.F. and Gomez, R.S. (2012) Epigenetic Regulation of Matrix Metalloproteinase Expression in Ameloblastoma. BMC Clinical Pathology, 12, Article No. 11. https://doi.org/10.1186/1472-6890-12-11
[28]
Khojasteh, A., Khodayari, A., Rahimi, F., Ghaderian, M.H., Jafarian, M., Nayebi, A., Akbarzadeh Najar, R., Tabatabayipanah, A. and Jahangirnia, A. (2013) Hypermethylation of p16 Tumor-Suppressor Gene in Ameloblastic Carcinoma, Ameloblastoma, and Dental Follicles. Journal of Oral and Maxillofacial Surgery, 71, 62-65. https://doi.org/10.1016/j.joms.2012.04.033
[29]
Martinez-Martinez, M., Mosqueda-Taylor, A., Carlos-Bregni, R., Pires, F.R., Delgado-Azanero, W., Neves-Silva, R., Aldape-Barrios, B. and Paes-de Almeida, O. (2017) Comparative Histological and Immunohistochemical Study of Ameloblastoma and Ameloblastic Carcinomas. Medicina Oral Patologia Oraly Cirugia Bucal, 22, e324-e332. https://doi.org/10.4317/medoral.21901
[30]
Helmbold, P., Lahtz, C., Herpel, E., Schnabel, P.A. and Dammann, R.H. (2009) Frequent Hypermethylation of RASSF1A Tumour Suppressor Gene Promoter and Presence of Merkel Cell Polyomavirus in Small Cell Lung Cancer. European Journal of Cancer, 45, 2207-2211. https://doi.org/10.1016/j.ejca.2009.04.038
[31]
Kiuru, M., Tartar, D.M., Qi, L., Chen, D., Yu, L., Konia, T., McPherson, J.D., Murphy, W.J. and Fung, M.A. (2018) Improving Classification of Melanocytic Nevi: BRAF V600E Expression Associated with Distinct Histomorphologic Features. Journal of the American Academy of Dermatology, 79, 221-229. https://doi.org/10.1016/j.jaad.2018.03.052
[32]
Zhao, J., Cui, X., Huang, X., Lu, R., Chen, P. and Zhang, Z. (2019) Methylation of RUNX3 and RASSF1A and the Risk of Malignancy in Small Solitary Pulmonary Nodules. Journal of Cancer Research and Therapeutics, 15, 899-903. https://doi.org/10.4103/jcrt.JCRT_790_18
[33]
Wang, T., Liu, H., Chen, Y., Liu, W., Yu, J. and Wu, G. (2009) Methylation Associated Inactivation of RASSF1A and Its Synergistic Effect with Activated K-Ras in Nasopharyngeal Carcinoma. Journal of Experimental and Clinical Cancer Research, 28, 160. https://doi.org/10.1186/1756-9966-28-160
[34]
Hagrass, H.A., Pasha, H.F., Shaheen, M.A., Abdel Bary, E.H. and Kassem, R. (2014) Methylation Status and Protein Expression of RASSF1A in Breast Cancer Patients. Molecular Biology Reports, 41, 57-65. https://doi.org/10.1007/s11033-013-2837-3
[35]
Rezk, N.A., Mohamed, R.H., Alnemr, A.A. and Harira, M. (2018) Promoter Methylation of RASSF1A Gene in Egyptian Patient with Ovarian Cancer. Applied Biochemistry and Biotechnology, 185, 153-162. https://doi.org/10.1007/s12010-017-2648-4
[36]
Joo, M.K., Kim, K.H., Park, J.J., Yoo, H.S., Choe, J., Kim, H.J., Lee, B.J., Kim, J.S. and Bak, Y.T. (2015) CpG Island Promoter Hypermethylation of Ras Association Domain Family 1A Gene Contributes to Gastric Carcinogenesis. Molecular Medicine Reports, 11, 3039-3046. https://doi.org/10.3892/mmr.2014.3055
[37]
Schirosi, L., Mazzotta, A., Opinto, G., Pinto, R., Graziano, G., Tommasi, S., Fucci, L., Simone, G. and Mangia, A. (2016) β-Catenin Interaction with NHERF1 and RASSF1A Methylation in Metastatic Colorectal Cancer Patients. Oncotarget, 7, 67841-67850. https://doi.org/10.18632/oncotarget.12280
[38]
Dubois, F., Keller, M., Calvayrac, O., Soncin, F., Hoa, L., Hergovich, A., Parrini, M.C., Mazières, J., Vaisse-Lesteven, M., Camonis, J., Levallet, G. and Zalcman, G. (2016) RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/ RhoB Pathway. Cancer Research, 76, 1627-1640. https://doi.org/10.1158/0008-5472.CAN-15-1008
[39]
Dumaz, N., Jouenne, F., Delyon, J., Mourah, S., Bensussan, A. and Lebbe, C. (2019) Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Cancers, 11, 1133. https://doi.org/10.3390/cancers11081133
[40]
Singarayer, R., Mete, O., Perrier, L., Thabane, L., Asa, S.L., Van Uum, S., Ezzat, S., Goldstein, D.P. and Sawka, A.M. (2019) A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. Endocrine Pathology, 30, 201-218. https://doi.org/10.1007/s12022-019-09585-2
[41]
Zhang, R., Yang, Q., Li, T., Qu, J., Hong, Y. and Liu, P. (2020) The BRAF p.V600E Mutation Is a Common Event in Ameloblastomas But Is Absent in Odontogenic Keratocysts. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 1-7. https://doi.org/10.1016/j.oooo.2019.04.001
[42]
van Engeland, M., Roemen, G.M., Brink, M., Pachen, M.M., Weijenberg, M.P., de Bruïne, A.P., Arends, J.W., van den Brandt, P.A., de Goeij, A.F. and Herman, J.G. (2002) K-Ras Mutations and RASSF1A Promoter Methylation in Colorectal Cancer. Oncogene, 21, 3792-3795. https://doi.org/10.1038/sj.onc.1205466
[43]
Xing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P.W. and Sidransky, D. (2004) Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis. Cancer Research, 64, 1664-1668. https://doi.org/10.1158/0008-5472.CAN-03-3242
[44]
Reifenberger, J., Knobbe, C.B., Sterzinger, A.A., Blaschke, B., Schulte, K.W., Ruzicka, T. and Reifenberger, G. (2004) Frequent Alterations of Ras Signaling Pathway Genes in Sporadic Malignant Melanomas. International Journal of Cancer, 109, 377-384. https://doi.org/10.1002/ijc.11722
[45]
Oliveira, C., Velho, S., Domingo, E., Preto, A., Hofstra, R.M., Hamelin, R., Yamamoto, H., Seruca, R. and Schwartz, S.Jr. (2005) Concomitant RASSF1A Hypermethylation and KRAS/BRAF Mutations Occur Preferentially in MSI Sporadic Colorectal Cancer. Oncogene, 24, 7630-7634. https://doi.org/10.1038/sj.onc.1208906
